$BMRN Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.23 up 91.67% YoY
• Reported revenue of $1.02B up 32.02% YoY
• BioMarin updated FY2026 guidance to total revenues of $3.8B, Metabolic Conditions $2.68B, VOXZOGO $975M, and Non-GAAP Diluted EPS $2.80 to $3.10.